Haloprogin

CHEMBL1289 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
361.4 g/mol
LogP
4.6
Phase
4

A topical antifungal agent used to treat superficial fungal infections of the skin including tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). It works by disrupting the fungal cell membrane, causing leakage of cellular contents. It has largely been replaced by newer antifungals with improved efficacy and tolerability.

Moleküler Ağırlık

361,4000 g/mol

LogP

4,60

TPSA

9,20 Ų

Lipinski RO5

Geçer

Etki Mekanizması

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Clc1cc(Cl)c(OCC#CI)cc1Cl

InChI

InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2

Molecular Formula

C9H4Cl3IO

HBD / HBA

- / 1

Döndürülebilir Bağlar

2

Ağır Atomlar

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A topical antifungal agent used to treat superficial fungal infections of the skin including tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). It works by disrupting the fungal cell membrane, causing leakage of cellular contents. It has largely been replaced by newer antifungals with improved efficacy and tolerability.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Haloprogin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1289. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3561. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.